Therapeutics & Vaccines
Synthesis of Novel Small Molecule CARM1 Degraders, Compounds Formed Thereby, and Pharmaceutical Compositions Containing Them
WARF: P230336US02
Inventors: Weiping Tang, Wei Xu, Haibo Xie, Megan Bacabac
The Invention
UW-Madison researchers have developed a focused library of CARM1 protein degraders. These degraders used a known binding molecule of CARM1 with an optimized linker attached to a Von Hippel–Lindau (VHL) ligand that recruits a ubiquitin ligase to CARM1. Upon ubiquitination, the cell removes CARM1 protein. They showed that their lead molecule can selectively degrade CARM1. The degradation of the protein leads to a reduction in mobility of triple negative breast cancer cells.
There didn’t appear to be any effect on cell growth or proliferation. More work will need to be done to determine whether degradation of CARM1 is a validated cancer therapeutic strategy.
Additional Information
For More Information About the Inventors
Tech Fields
For current licensing status, please contact Rafael Diaz at [javascript protected email address] or 608-960-9847